Table 2.
Annual prevalence (2003–2008) of pharmacologically treated ADHD (methylphenidate, dexamfetamine and atomoxetine) by age category and gender
| Age Category | Year | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 |
|---|---|---|---|---|---|---|---|
|
Total Prevalence*1000 (Males and Females ≥ 6 years) |
0.709 |
0.862 |
1.014 |
1.203 |
1.365 |
1.403 |
|
| 95% Cl (lb)*1000 |
0.676 |
0.825 |
0.975 |
1.161 |
1.320 |
1.358 |
|
| 95% Cl (ub)*1000 |
0.743 |
0.899 |
1.054 |
1.246 |
1.411 |
1.449 |
|
|
6-12 years | |||||||
|
Female Prevalence*1000 |
1.339 |
1.642 |
2.042 |
2.310 |
2.775 |
2.769 |
|
| 95% Cl (lb)*1000 |
1.131 |
1.411 |
1.784 |
2.034 |
2.470 |
2.464 |
|
| 95% Cl (ub)*1000 |
1.574 |
1.900 |
2.327 |
2.613 |
3.108 |
3.101 |
|
|
Male Prevalence*1000 |
8.147 |
9.758 |
11.133 |
13.224 |
15.432 |
15.321 |
|
| 95% Cl (lb)*1000 |
7.634 |
9.195 |
10.532 |
12.566 |
14.716 |
14.607 |
|
| 95% Cl (ub)*1000 |
8.685 |
10.346 |
11.759 |
13.907 |
16.174 |
16.061 |
|
|
Total Prevalence*1000 |
4.825 |
5.795 |
6.688 |
7.886 |
9.241 |
9.181 |
|
| 95% Cl (lb)*1000 |
4.543 |
5.485 |
6.355 |
7.522 |
8.844 |
8.786 |
|
| 95% Cl (ub)*1000 |
5.121 |
6.119 |
7.034 |
8.262 |
9.651 |
9.590 |
|
|
13-17 years | |||||||
|
Female Prevalence*1000 |
0.635 |
0.947 |
1.106 |
1.446 |
1.767 |
2.002 |
|
| 95% Cl (lb)*1000 |
0.465 |
0.742 |
0.890 |
1.201 |
1.497 |
1.714 |
|
| 95% Cl (ub)*1000 |
0.847 |
1.191 |
1.360 |
1.727 |
2.071 |
2.325 |
|
|
Male Prevalence*1000 |
6.250 |
7.535 |
9.104 |
11.027 |
11.752 |
12.569 |
|
| 95% Cl (lb)*1000 |
5.719 |
6.963 |
8.485 |
10.350 |
11.054 |
11.845 |
|
| 95% Cl (ub)*1000 |
6.818 |
8.141 |
9.757 |
11.737 |
12.483 |
13.325 |
|
|
Total Prevalence*1000 |
3.608 |
4.404 |
5.265 |
6.378 |
6.865 |
7.396 |
|
| 95% Cl (lb)*1000 |
3.314 |
4.087 |
4.925 |
6.008 |
6.484 |
6.999 |
|
| 95% Cl (ub)*1000 |
3.921 |
4.739 |
5.622 |
6.765 |
7.264 |
7.810 |
|
|
18-24 years | |||||||
|
Female Prevalence*1000 |
0.118 |
0.116 |
0.112 |
0.244 |
0.337 |
0.335 |
|
| 95% Cl (lb)*1000 |
0.059 |
0.058 |
0.056 |
0.158 |
0.236 |
0.237 |
|
| 95% Cl (ub)*1000 |
0.211 |
0.207 |
0.200 |
0.361 |
0.466 |
0.460 |
|
|
Male Prevalence*1000 |
0.396 |
0.521 |
0.845 |
0.943 |
1.385 |
1.876 |
|
| 95% Cl (lb)*1000 |
0.283 |
0.391 |
0.679 |
0.770 |
1.178 |
1.637 |
|
| 95% Cl (ub)*1000 |
0.540 |
0.680 |
1.038 |
1.142 |
1.619 |
2.140 |
|
|
Total Prevalence*1000 |
0.263 |
0.327 |
0.493 |
0.607 |
0.878 |
1.122 |
|
| 95% Cl (lb)*1000 |
0.196 |
0.253 |
0.402 |
0.507 |
0.759 |
0.989 |
|
| 95% Cl (ub)*1000 |
0.346 |
0.417 |
0.599 |
0.721 |
1.010 |
1.267 |
|
|
25-45 years | |||||||
|
Female Prevalence*1000 |
0.008 |
0.026 |
0.028 |
0.040 |
0.045 |
0.052 |
|
| 95% Cl (lb)*1000 |
0.002 |
0.012 |
0.014 |
0.023 |
0.027 |
0.032 |
|
| 95% Cl (ub)*1000 |
0.023 |
0.047 |
0.050 |
0.065 |
0.071 |
0.079 |
|
|
Male Prevalence*1000 |
0.025 |
0.038 |
0.052 |
0.074 |
0.095 |
0.105 |
|
| 95% Cl (lb)*1000 |
0.012 |
0.021 |
0.032 |
0.050 |
0.068 |
0.076 |
|
| 95% Cl (ub)*1000 |
0.046 |
0.062 |
0.079 |
0.105 |
0.130 |
0.141 |
|
|
Total Prevalence*1000 |
0.017 |
0.032 |
0.040 |
0.057 |
0.070 |
0.079 |
|
| 95% Cl (lb)*1000 |
0.009 |
0.021 |
0.027 |
0.042 |
0.053 |
0.061 |
|
| 95% Cl (ub)*1000 |
0.028 |
0.047 |
0.056 |
0.076 |
0.091 |
0.100 |
|
|
>45 years | |||||||
|
Female Prevalence*1000 |
0.007 |
0.011 |
0.007 |
0.010 |
0.010 |
0.011 |
|
| 95% Cl (lb)*1000 |
0.002 |
0.004 |
0.002 |
0.004 |
0.004 |
0.005 |
|
| 95% Cl (ub)*1000 |
0.018 |
0.023 |
0.018 |
0.022 |
0.022 |
0.024 |
|
|
Male Prevalence*1000 |
0.008 |
0.008 |
0.015 |
0.015 |
0.020 |
0.027 |
|
| 95% Cl (lb)*1000 |
0.002 |
0.002 |
0.007 |
0.006 |
0.010 |
0.015 |
|
| 95% Cl (ub)*1000 |
0.020 |
0.020 |
0.030 |
0.029 |
0.036 |
0.044 |
|
|
Total Prevalence*1000 |
0.008 |
0.009 |
0.011 |
0.012 |
0.015 |
0.019 |
|
| 95% Cl (lb)*1000 |
0.003 |
0.004 |
0.006 |
0.007 |
0.009 |
0.012 |
|
| 95% Cl (ub)*1000 | 0.015 | 0.017 | 0.019 | 0.021 | 0.024 | 0.028 | |
CI (Confidence Interval), lb (lower boundary) and ub (upper boundary).